1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2019-2024

Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2019-2024

  • February 2019
  • 222 pages
  • ID: 5730664
  • Format: PDF

Summary

Table of Contents

Search Inside

The global premature ejaculation therapeutics market is estimated to reach revenues of approximately $3 billion by 2024, growing at a CAGR of around 9% during 2018-2024.

The entry of new vendors is leading to high capital investment for R&D activities and manufacturing of new prescription drugs in the global market. The increasing awareness and focus on sexual wellness will create lucrative opportunities for leading vendors operating in the market.The global premature ejaculation therapeutics market is driven by growing patient willingness to seek pharmaceutical therapy assistance for disease management. The launch of off-label drugs belonging to SSRIs and topical formulations will revolutionize the global market over the next few years. The market research report provides in-depth market analysis and segmental analysis of the global premature ejaculation therapeutics market by drug class, ROA, and geography.

The report considers the present scenario of the global premature ejaculation therapeutics market and its market dynamics for the period 2019'2024. It covers a detailed overview of various market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes the leading companies and various other prominent companies operating in the market.

Premature Ejaculation Therapeutics Market – Dynamics

PE is one of the common sexual disorders prevalent in men. Many results from many epidemiological studies, PE is considered to be the most prevalent sexual disorder in men. Globally, the prevalence rate of PE is in the range of 25% to 40% in men across all age groups. As per estimates, the prevalence of PE is more than 20% in regions like Europe, APAC, Latin America, and North America. The Middle East and African regions have a prevalence rate of 13% and 11% respectively. The existence of non-pharmacological treatment modalities, multiple international and regional guidelines recommend the administration of pharmacological agents (alone or in a combination of behavioral techniques/psychological therapy and drug therapy) as the first-line option for the management of the lifelong or acquired PE. The prime factor in the recommendation of drug therapy is its superiority than other non-pharmacological therapies. In addition, many research studies confirmed that therapeutic intervention with various available drugs is effective in improving the signs and symptoms of PE.Pharmaceutical advances are continually leading to the innovation of new drug formulations and drug delivery systems. These advances are improving the efficacy and safety of drugs by enhancing bioavailability, improving drug absorption and modifying the rate of drug release.

Premature Ejaculation Therapeutics Market – Segmentation

This market research report includes a detailed segmentation of the market by drug class, ROA, and geography.The global premature ejaculation therapeutics market by drug class is segmented into SSRIs, PDE5 inhibitors, anesthetic agents, and others. SSRIs segment dominated more than 1/3rd of the total market share in 2018, growing at a CAGR of more than 8% during the forecast period. SSRIs is the most common type of drug for premature ejaculation treatment, and the introduction of Priligy (dapoxetine), which gained regulatory approval in 2009 is fueling the growth of this segment in the global market.Some of the common brand names of PDE5 inhibitors that are available in the global market include Cialis, Viagra, and Levitra. The plethora of unlicensed formulations, comprising anesthetic drugs and anesthetic agents will lead to an increase in clinical trials in the market.

The ROA segment in the global premature ejaculation therapeutics market is classified into oral therapeutics and topical therapeutics. Topical therapeutics is the fastest growing segment in the global market, at a CAGR of over 10% during the forecast period. The continual approval for new topical OTC formulations, rise in product uptake of existing products due to increase in disease awareness, and interest of couples for sexual wellbeing are some of the factors attributing to the growth of this segment in the global market.The daily dose oral therapies can exhibit improved and enhanced efficacy over topical therapies for treating PE. Some of the leading off-label oral formulation brands available in the global premature ejaculation therapeutics market are Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro.

Market Segmentation by Drug Class
• SSRIs
• PDE5 Inhibitors
• Anesthetic Agents
• Others

Market Segmentation by ROA
• Oral Therapeutics
• Topical Therapeutics

Premature Ejaculation Therapeutics Market – Geography

The global premature ejaculation therapeutics market by geography is categorized into North America, Europe, APAC, Latin America, and MEA. North America occupied the largest market share in 2018, growing at a CAGR of around 9% during the forecast period. The rising lifestyle-related stress, the rise in chronic conditions, which can lead to the incidence of PE, increases in cancers, especially prostate cancer is fueling the growth of the North American region in the global market.The high disease prevalence population, improvement in healthcare spending, increase in PE awareness, increase in uptake of PE drugs especially the off-label generic medicines, and low-cost OTC drugs are fueling the demand across the APAC region in the global premature ejaculation therapeutics market.

Market Segmentation by Geography
• North America
o US
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
• APAC
o Japan
o India
o China
o Australia
• Latin America
o Brazil
o Mexico
• MEA

Key Vendor Analysis
The global premature ejaculation therapeutics market is fairly fragmented due to the presence of pharma companies and generic manufacturers. The top vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents to attract the maximum number of consumers in the global market. The exponential growth of the APAC and Latin American region will create lucrative investment opportunities for prominent players in the market. Factors such as access to drugs, high disease awareness, and high affordability will help companies boost revenues in the global premature ejaculation therapeutics market.

The major vendors in the global market are:
• Absorption Pharmaceuticals
• INNOVUS PHARMACEUTICALS
• Pfizer
• Plethora Solutions Holdings

Other prominent vendors include Bayer, Eli Lilly and Company, GlaxoSmithKline, Recordati, Royalty Pharma, The Menarini Group, Ixchelsis.

Key market insights include
1. The analysis of global premature ejaculation therapeutics market provides market size and growth rate for the forecast period 2019-2024.
2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global premature ejaculation therapeutics market.
3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
4. It offers a complete overview of market segments and the regional outlook of global premature ejaculation therapeutics market.
5. The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Erectile Dysfunction - Pipeline Review, H1 2019

Erectile Dysfunction - Pipeline Review, H1 2019

  • $ 2000
  • February 2019

Erectile Dysfunction - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2019, provides an ...

Aesthetic Devices - Medical Devices Pipeline Assessment, 2019

Aesthetic Devices - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • February 2019

Aesthetic Devices - Medical Devices Pipeline Assessment, 2019SummaryGlobalData’s Medical Devices sector report, “Aesthetic Devices - Medical Devices Pipeline Assessment, 2019" provides an overview ...

2019 Future of Metachromatic Leukodystrophy (MLD) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

2019 Future of Metachromatic Leukodystrophy (MLD) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • $ 2199
  • February 2019

7 Companies Make Active Investments in Metachromatic Leukodystrophy (MLD) Pipeline DrugsThe global demand for Metachromatic Leukodystrophy (MLD) treatment options is emerging rapidly driven by demand in ...

Colitis - Pipeline Review, H1 2019 $ 2000 February 2019


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on